The cytochrome P450 2D6 (CYP2D6) is a genetically polymorphic enzyme involved in the metabolism of several psychoactive drugs. Beside its expression in the liver, CYP2D6 is highly expressed in several regions of the brain, such as the hippocampus, thalamus, hypothalamus and the cortex, but its function in the brain is not well understood. The CYP2D6 enzyme may also have a physiological role due to its involvement in neurotransmitter biotransformation. In this study, CYP2D6 genotyping was performed in N = 188 healthy individuals and compared with brain perfusion levels at rest, which may reflect an ongoing biological process regulating the reactivity of the individual to emotional stimuli and the detection of signals evoking fear. Relative to N = 42 matched extensive metabolizers, N = 14 poor metabolizers were associated with 15% higher perfusion levels in the thalamus (P = 0.03 and 0.003). Effects were also present in the whole (N = 188) sample divided into metabolizer groups, or finely graded into seven CYP2D6 activity levels. A weaker effect was observed in the right hippocampus (P = 0.05). An exploratory analysis, extended to the whole brain, suggested the involvement of CYP2D6 in regions associated with alertness or serotonergic function. These findings support the hypothesis of a functional role of CYP2D6 in the brain.
Introduction
Cytochrome P450 2D6 (CYP2D6) is an enzyme involved in the metabolism of many drugs active in the central nervous system, such as antidepressants, antipsychotics and central opioids. 1 This enzyme is coded by a polymorphic gene, with 7% of the Caucasian population showing no enzymatic activity ('poor metabolizers'). Approximately 20-30% of Caucasians carry one active and one inactive allele, and show intermediate enzyme activity (here referred to as 'intermediate metabolizers').
2 Individuals carrying two active alleles are 'extensive metabolizers'. Beside its expression in the liver, CYP2D6 is widely expressed in the brain, but its function there is not well understood. In man, CYP2D6 messenger RNA and protein have been shown to be expressed in neurons, with preferential localization in the hippocampal cortex, thalamus, hypothalamus, substantia nigra, cerebellum, and layers III and V of neocortex. 3 Hypotheses on the role of CYP2D6 in the brain vary. 4 The enzyme, CYP2D6, has been shown in in vitro studies to have a role in the biotransformation of precursors to endogenous transmitters, such as serotonin and dopamine. 5, 6 Recently, it has also been shown that CYP2D6 may have a role in morphine biosynthesis 7 and in the metabolism of the endocannabinoid anandamide. 8 However, evidence of increased regional expression in alcoholism 9 and under nicotine administration 10, 11 suggests a role in the extrahepatic biotransformation of exogenous substances, analogous to its role in the liver.
On the basis of these findings, some studies have attempted to establish an association between a personality phenotype and CYP2D6 genotype. [12] [13] [14] Specifically, the poor metabolizer phenotype is thought to be associated with an anxious personality trait. 15, 16 However, no consistent phenotype has been detected in other studies. [17] [18] [19] [20] Therefore, current knowledge of the role of CYP2D6 is limited to its biochemical function, but lacks any specification of an in vivo phenotype. Studies on the putative effects of the CYP2D6 genotype in man have attempted to identify its phenotype at a very general behavioral or personality trait level, whereas studies attempting to localize these possible effects in terms of characterized neurobiological systems have not been performed, thus failing to make use of neuroanatomical knowledge of its preferential expression.
When measured at rest, brain perfusion is a wellcharacterized index of cerebral activity, [21] [22] [23] thought to support the capacity of the individual to react to environmental stimuli quickly and specifically. 24 This functional interpretation of rest perfusion depends on the observation of its modulation in specific structures in the wake-sleep cycle 25, 26 and during pathological states, such as depression, 27 ,28 which may also be viewed as conditions of altered vigilance for specific classes of environmental stimuli. 29 Furthermore, considerable variation in rest perfusion levels is present in normal individuals, 30 some of which may be associated with personality traits, 31 or with genetic polymorphisms with possible relevance for vulnerability to depression and anxiety. 32, 33 However, a significant portion of the variation in perfusion levels between individuals is yet to be explained.
In this study, we used an advanced arterial spin labeling technique (continuous arterial spin labeling, CASL 34 ) to seek the influence of CYP2D6 polymorphism in the levels of resting brain perfusion. To increase the power of the study, we focused on two a priori defined regions of interest, the hippocampus and the thalamus, in which this gene is preferentially expressed and the continuous arterial spin labeling signal is reliable. We also included the basal ganglia as a control region, in which the perfusion rate should have been unaffected by CYP2D6 genotype. 3, 9 This first analysis was followed by an explorative analysis of the effects of CYP2D6 polymorphism in the whole brain.
Materials and methods

Sample selection
Participants of central European origin were recruited from local schools and university and by local announcements. Exclusion criteria were neurological or medical conditions, use of medication, alcohol or drug abuse or a history of mental illness, and the presence of subclinical structural abnormalities in standard clinical imaging. The sample thus obtained has been described previously, 30 and consists of resting perfusion data collected with the same methodology in three studies after obtaining informed consent for both image acquisition and genotyping. Blind to genotype, perfusion images were individually checked for the presence of movement artifacts or problems in the quantification of cerebral blood flow (CBF), discarding 3 participants. Other participants gave no consent to genotyping, leaving a sample of N = 188 in which CYP2D6 genotype could be determined. The study protocol was approved by the institutional ethics committee and was performed in compliance with national legislation and the Code of Ethical Principles for Medical Research Involving Human Subjects of the World Medical Association.
Genotyping
The CYP2D6 genotyping was performed for detecting the inactive alleles: CYP2D6*3, *4, *5 and *6, and for detecting the gene duplication, decreased activity alleles CYP2D6*9, *10, *17 and *41, and the high activity alleles *2 and *35. Genotyping was performed with a combination of long PCR and primerextension method using the SNaPshot-Kit (Applied Biosystems, Mannheim, Germany) as described previously. 35, 36 The sequence between exon 9 of the upstream and intron 2 of the downstream CYP2D6 gene copy of the duplicated CYP2D6 allele was amplified using duplication-specific long PCR. The PCR reaction was performed using primer set CYP2D6-F: To code the phenotype, genotypes were assigned to three groups according to the number of deficient activity alleles (CYP2D6*3, *4, *5 and *6), resulting in a CYP2D6-poor metabolizer phenotype for carriers of two deficient activity alleles, an intermediate metabolizer phenotype for individuals with one deficient activity allele, and an extensive metabolizer phenotype for individuals lacking any deficient activity allele. The CYP2D6 activity score was calculated according to the methods published earlier. 37 Image acquisition and preprocessing All magnetic resonance imaging (MRI) data were obtained with a 3-Tesla Magnetom Allegra (Siemens, Erlangen, Germany) MRI system equipped with a head volume coil. All participants were scanned at the Department of Psychiatry of the University of Ulm. A standard T2-weighted structural brain scan from the clinical screening routine in use in our hospital (TR (repetition time) 4120, TE (echo time) 82) was taken on all participants to exclude subclinical structural abnormalities. During the measurement of baseline perfusion, participants were asked to lie quietly in the scanner with closed eyes without falling asleep. A continuous arterial spin-labeling technique was used as described previously 34 . Interleaved images with and without labeling were acquired for 8 min (120 scans) by using a gradient-echo echoplanar imaging sequence with a field of view of 22 cm. Image size was 64 Â 64 Â 15 voxels, slice thickness 6 mm with a gap of 1.5 mm, giving a voxel size of 3.44 Â 3.44 Â 7.50 mm. The images were acquired with an echo-planar imaging sequence with TR 4000, TE 17, anterior-to-posterior phase encoding, a flip angle of 901, and a bandwidth of 3005 Hz per pixel. A 1-s delay was inserted between the end of the labeling pulse and image acquisition to reduce transit artifacts.
The SPM2 (statistical parametric mapping) package was used (Wellcome Department of Cognitive Neurology, London, UK; online at http://www.fil.ion.ucl. ac.uk) for realignment and stereotactic normalization to an echo-planar imaging template (Montreal Neurological Institute, Montreal, Quebec, Canada; resampling size: 2 Â 2 Â 2 mm). Reconstruction of rCBF values was obtained using software implementing equation (1) in the study by Wang et al. 38 The 'simple subtraction' method was used. All volumes were smoothed using an isotropic Gaussian kernel of full width half-maximum 8 mm. For the whole brain analysis, an explicit mask was obtained by thresholding the a priori thresholded tissue probability maps provided by the SPM package at 0.25 for gray or white matter. The cerebellar region and the lower brainstem were excluded manually in this mask because they were affected by large variance, which may be of artifactual nature in our images (these regions are close to where the labeling pulse is given). For the analyses of a priori region of interest, anatomical regions (hippocampus and thalamus, basal ganglia, including putamen, globus pallidus, and nucleus caudatus) were drawn using the map 'aal.img' shipped with the freely available program MRIcroN, obtained from the website www.sph.sc.edu/comd/ rorden/mricron/.
Statistical analysis
Effect of CYP2D6 genotype was first tested in two regions of interest selected a priori on the basis of published expression studies, 3, 9 and then on the whole brain in a second analysis with exploratory character, using the statistical mapping approach. 39 As the frequency of poor metabolizers, in which the effect may be strongest, is very low in the population, and the multiple effect on CYP2D6 activity by multiallelic variation may not be linear, we used matching 40, 41 to select a sample contrasting poor with extensive metabolizers. We then used the full sample to characterize the shape of the effect of the whole genotypic variation spectrum in the region of interest in which the effect detected by the matched analysis was strongest.
The matched sample was obtained by matching the 14 individuals, with two alleles coding deficient enzyme activity (poor metabolizers), with 42 individuals without any deficient activity allele (extensive metabolizers) by age, sex, the time in which scan was conducted (rated in months) and study (as images were acquired in two main batches) using the freely available program MatchIt, obtained from the website www.stat.lsa.umich.edu/~bbh/optmatch.html. 42, 43 Matching 1 poor metabolizer to 3 extensive metabolizers was done to improve the detection power and reduce model dependence (Rosenbaum 41 , Chapter 10). After matching, participants with these two genotypes did not significantly differ in sex (logistic regression, z = 0.45, P = 0.7, two-tailed), age (z = 0.19, P = 0.8), scan period (z = À0.23, P = 0.8) or study (z = À0.01, P = 0.99). The 'optimal matching' algorithm was used. 41, 44 This and other univariate models were estimated using the freely available statistical program R (version 2.9.2, available from www.rproject.org, The R Foundation for Statistical Computing, Vienna, Austria).
The model used to analyze CBF data included CYP2D6 phenotype as the primary covariate of interest, and age, sex, scan period and study as nuisance covariates. After checking that it was not associated with CYP2D6 phenotype (matched sample, logistic regression, z = 0.45, P = 0.65; whole sample, t 182 = 0.22, P = 0.82), global CBF (the average perfusion across the brain in each individual) was also added as a nuisance covariate to the model. 45, 46 The same model was used to analyze both the matched and the whole samples.
In voxel-by-voxel analyses using the parametric mapping approach, images of the baseline perfusion signal in each individual were averaged after preprocessing and entered at the 'second level' of analysis to model subjects as a random factor. Second-level statistical analysis was performed on these averaged volumes using the same model and using a permutation method to obtain voxel-levelcorrected significance values. 47 Permutation tests do not rely on distributional assumptions and show generally superior power in neuroimaging applications. 48 Significance values for voxel, cluster and set level inferences were computed on the basis of the quantiles of the permutation distribution of the maximal t, the largest cluster of contiguous overthreshold voxels, and the number of overthreshold voxels, respectively. Clusters and sets were defined a priori by the univariate significance level 0.005, as in studies by Rao et al. 33 and Viviani et al.
49
, for the whole volume test, and 0.05 for tests in the regions of interest. In each test, 8000 permutations were computed. Computations were carried out in MATLAB R2006b (The Mathworks, Natick, MA, USA) installed on a machine equipped with a 64-bit Athlon processor (Advanced Micro Devices, Sunnyvale, CA, USA) CYP2D6 and resting brain perfusion J Kirchheiner et al running Windows XP (Microsoft, Redmond, WA, USA). For the generation of random numbers, the 'MATLAB5 generator' was used. Images were generated using the same application, MRIcroN, used to select the anatomical regions of interest (www.sph.sc.edu/comd/rorden/mricron/).
Results
In the whole sample, 14 individuals were poor metabolizers with two alleles coding deficient enzyme activity (CYP2D6*3, *4, *5 or *6); 69 individuals were carriers of one deficient activity allele (intermediate metabolizers); and the remaining 105 individuals carried no deficient activity allele (extensive metabolizers). The sample obtained through matching and the whole sample are described in Table 1 .
Analysis regions of interest hippocampus and thalamus
In the mean CBF analysis, perfusion levels were first averaged over the two regions of interest, the hippocampus and thalamus, on the left and right side, and the basal ganglia as a control region. Tests of CYP2D6 genotype effects in the linear model for the matched sample (poor vs extensive metabolizers) revealed that significant perfusion increases in poor metabolizers in all these regions except the left hippocampus (Table 2 , left). The evidence and the size of CYP2D6 genotype effects in the hippocampus, however, were considerably lower than in the thalamus. In this latter region, poor metabolizers were characterized by average increases of perfusion levels of 7.7 ml 100 g À1 min À1 relative to extensive metabolizers (s.d. = 2.7 ml 100 g À1 ml
À1
), corresponding to percent changes of 15% of baseline levels. No significant CYP2D6 genotype effects were detected in the control region of the basal ganglia.
Data for the whole sample are in Table 2 , right. Here, the mean perfusion is slightly lower than in the matched sample due to a preponderance of female participants. 30 Its analysis confirmed the existence of a significant linear effect of increased perfusion from extensive to poor metabolizers, with average effect sizes of about 1.9 ml 100 g À1 ml À1 (s.d. 1.1 ml 100 g À1 ml
) in the hippocampus, and about 5.4 ml 100 g À1 ml À1 (s.d. 2.0 ml 100 g À1 ml
) in the thalamus (Table 2, right). This effect may also be seen in the boxplots of Figure 1 , which are based on the whole sample. Except for the data from the left hippocampus, perfusion levels of intermediate metabolizers lay between those of poor and extensive metabolizers. Furthermore, in the whole sample also, no significant effect of CYP2D6 genotype was detected in the control region of the basal ganglia.
In Figure 2 , mean CBF perfusion levels in the thalamus and hippocampus were plotted on the whole spectrum of allelic variation on the CYP2D6 activity score. This score attempts to capture finely graded variation in enzymatic activity on the basis of the combinations of the ten most common alleles with known functional relevance (see Materials and methods), resulting in seven levels of activity. 37 In the thalamus, in which the CYP2D6 genotype effect was largest, we observed that CBF decreases with increasing CYP2D6 activity score (t 181 = 2.37, P = 0.02, two-tailed), leveling off at midrange in a slight nonlinearity of effect. In the rest of the analysis, we continued to use a three-group coding based on the number of deficient activity alleles (poor, intermediate and extensive metabolizers) to test genotype effects. In the hippocampus, evidence for activity scores effects was limited (t 181 = 1.00, n.s.). There was no significant interaction between laterality and activity scores in these regions (t 180 = 0.15 and t 180 = 0.22, n.s.). The voxel-by-voxel analysis of the regions of interest confirmed these findings, detecting significant activations at voxel level in the comparison between poor and extensive metabolizers in the left and right thalamus, whereas a trend was observed in the right hippocampus ( Figure 3 and 4, Table 3 ). Posthoc inspection of the overlaid t-values in the hippocampus revealed an unequal involvement of the hippocampal structure, selectively affecting the posterior and medial parts (Figure 4) . In the surround, there was a tendency of the association to extend inferiorly toward the parahippocampal cortex ( Figure  3, center) .
Voxel-by-voxel analysis extended to whole brain
In this analysis, CBF levels were regressed on CYP2D6 genotype in the whole brain voxel by voxel to verify the possible existence of associations outside the predefined regions of interest. Set level tests yielded a significant trend for a positive association with the poor metabolizer status in the matched sample (set level: P = 0.01, one-tailed), which was also present in the whole sample (P < 0.01). The effects in individual areas reported below survived a significance threshold of P < 0.001, uncorrected. As one can see from the top half of Figure 3 , apart from the areas of the region of interest analysis, the largest positive associations in the neocortex were observed in a diffuse area extending over the calcarine and occipital cortex (lingula, Brodmann area 18-27, t = 4.33 in the matched sample, t = 4.22 in the whole sample), in the precuneus (Brodmann area 17, t = 3.46 in the matched sample, t = 3.61 in the whole sample), and in the substantia innominata/orbitofrontal cortex (x, y, z = 18, 20, À14; 
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Mean hippocampal perfusion N=14 N=18 N=49 N=20 N=80 N=1 N=6 Figure 2 Box plots of adjusted average perfusion levels in the thalamus. On the x axis, cytochrome P450 2D6 (CYP2D6) activity is scored according to the study by Gaedigk et al. 37 Individuals with activity 0 in this plot are poor metabolizers. CBF: cerebral blood flow (in ml 100 g À1 min À1 ). The nonlinearity of this curve is significant as a quadratic term added to the linear CYP2D6 activity score (t 180 = 1.95, P = 0.05, two-tailed). t = 4.74, matched sample, and t = 3.48, whole sample). Positive associations were also noted in the hypothalamus (x, y, z = 2, À2, À10; t = 4.12, matched sample, and t = 4.42, whole sample), a structure expressing CYP2D6 at very high levels, 3 and in the raphe nucleus (x, y, z = 2, À30, À16; t = 2.70, matched sample, and t = 3.99). Effect plots for the CYP2D6 activity scores in the two areas of largest effect, the hypothalamus and the occipital/calcarine cortex, are in the bottom half of Figure 3 , showing similar CBF decreases with increasing CYP2D6 activity and the tendency to level-off at midrange.
In the striatum and caudate nucleus, there was no positive association between the presence of deficient activity alleles and perfusion levels that survived the uncorrected threshold for cluster and set definition; on the contrary, perfusion levels were generally lower (x, y, z = À14, 8, À2; left pallidum, t = À2.82, matched sample, and t = À2.83, whole sample). Similarly, in the rest of the neocortex, there was a weak, diffuse negative association with poor metabolizer status (P = 0.03, set-level correction).
Discussion
Owing to its involvement in the biotransformation of various bioactive substrates in the brain, such as neurotransmitters, endogenous morphines and endocannabinoids, a functional role of CYP2D6 in the brain has been the object of much speculation. In humans, however, no functional phenotype of CYP2D6 genetic polymorphism referring to brain function has been found in support of this hypothesis. In this study, we sought an association between resting brain perfusion and metabolizer status underlying possible commonalities between the effect of CYP2D6 polymorphism and brain perfusion at rest. The effect of CYP2D6 genotype was estimated on resting brain perfusion in regions of interest determined by high expression levels of CYP2D6 protein and messenger RNA. An effect was detected in these regions as an increase of perfusion levels in poor metabolizers. In the thalamus, in which the detected effect of decreased CYP2D6 activity was largest, poor metabolizers were characterized by an increase of about 15% in perfusion levels compared with For illustration purposes, t-values were thresholded at the significance level P = 0.05, uncorrected. L, left; R, right; A, anterior; P, posterior. Bottom half: box plots of mean adjusted cerebral blood flow (CBF) perfusion in the hypothalamus (t 181 = 3.66, P < 0.001) and occipital/calcarine region (t 181 = 3.52, P < 0.001), divided by CYP2D6 activity scores as according to the study by Gaedigk et al. 37 . Individuals with activity 0 in this plot are poor metabolizers. CBF: cerebral blood flow (in ml 100 g À1 min
À1
).
CYP2D6 and resting brain perfusion J Kirchheiner et al extensive metabolizers. Intermediate metabolizers lay in between. In the hippocampus, the effect was weaker and mainly affected the posterior portion, consistent with the position of the dentate gyrus, in which CYP2D6 expression is largest. 3 As the concentration of CYP2D6 in the brain is low and restricted to neuronal cells, 3 it is not surprising that any effect, if it exists, may be detected in areas of high neuronal density and comparably high expression levels. In this study, no effect could be detected in regions with known low or absent expression of CYP2D6, such as the caudatus or the putamen. Outside the defined regions of interest, there was some evidence for a similar genotype effect in the hypothalamus, raphe nucleus and occipital cortex ( Figure 3) .
As CYP2D6 is involved in the transformation of several bioactive compounds in the brain, it is difficult to attribute any effect of CYP2D6 genotype to a single functional pathway. One possible key for understanding the functional role of CYP2D6 comes from a recent study showing its involvement in the synthesis of endogenous morphine. 7 Poor metabolizers might have lower endorphin levels, and show higher resting brain perfusion in those regions in which CYP2D6-mediated biotransformation is quantitatively important. Interestingly, the thalamus is a diencephalic nucleus also involved in nociception. 50, 51 In this region, individual differences in sensitivity to pain are associated with differences in activity. 52 In addition, the thalamus is an important relay centre for the reticular ascending system, which regulates arousal and alertness. [53] [54] [55] Thalamic perfusion is associated with alertness levels 25, 56 and is substantially reduced during sleep. 26 The association with perfusion levels in the substantia innominata/ orbitofrontal cortex and the occipital calcarine cortex is also consistent with involvement of a network subserving alertness. 56 Therefore, our findings raise the question of whether genotype differences may be associated with modulations of the thalamus affecting the reactivity to potentially harmful stimuli, or sustained attention/alertness.
In some studies investigating the relationship between CYP2D6 genotype and personality, an association was found between the poor metabolizer genotype and trait anxiety. 15, 16 The hippocampus has been shown to be involved in the regulation of anxiety. 57 However, only limited evidence was found for an effect of CYP2D6 activity on perfusion in this region. A possible perspective for future studies concerns the clarification of the relations between anxiety, CYP2D6, and the hippocampus.
In the exploratory analysis, CYP2D6 effects in the hypothalamus co-localized with high CYP2D6 expression levels. As a similar effect was also observed in the raphe nucleus, and both regions are characterized by high serotonin turnover and transporter density, 58 it is possible to speculate that the involvement of CYP2D6 in the serotonergic metabolism might be the mechanism at the basis of the changes in these regions.
There are several limitations potentially affecting this study. First, although our sample of 188 normal participants is comparatively large for MRI standards, the occurrence rate of 7% poor metabolizers in the population 59, 60 led to only 14 individuals being carriers of two deficient activity alleles. Second, as in any other observational study, unidentified covariates may be a source of hidden bias potentially affecting effect estimates. 41 Although the data were matched and adjusted for age, sex and time of the study, we may have failed to condition for unknown variables that could conceivably have an association with individual levels of rest perfusion, such as smoking status and, less likely in our sample, heavy alcohol abuse. Smoking and alcoholism has been reported to affect CYP2D6 expression in certain regions in the brain. 9, 10 However, the brain regions in which CYP2D6 induction was observed in these studies (globus pallidus, substantia nigra and cerebellum) were different from those detected here. Taken together, these findings support the hypothesis of a functional role of CYP2D6 in the brain. An interesting issue for future neuroimaging studies is the existence of effects of CYP2D6 genotype in tasks that specifically rely on the regions found to be associated with its expression and activity. Studies identifying intermediate phenotypes will be crucial in understanding the function of CYP2D6 in the brain.
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